Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Rebecca A DentSung-Bae KimMafalda OliveiraCarlos Henrique BarriosJoyce O'ShaughnessySteven Jay IsakoffShigehira SajiRui Gilberto FerreiraManuel PhilcoIgor BondarenkoQinshu LianDenise BradleyHeather HintonMatthew J WongchenkoSarah-Jayne ReillyNicholas C TurnerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Adding ipatasertib to paclitaxel did not improve efficacy in PIK3CA/AKT1/PTEN-altered advanced TNBC. Biomarkers for benefit from PI3K/AKT pathway inhibition in TNBC remain poorly understood.
Keyphrases
- phase iii
- locally advanced
- cell proliferation
- squamous cell carcinoma
- pi k akt
- signaling pathway
- open label
- rectal cancer
- clinical trial
- neoadjuvant chemotherapy
- phase ii
- phase ii study
- radiation therapy
- double blind
- small cell lung cancer
- placebo controlled
- protein kinase
- chemotherapy induced
- randomized controlled trial